8-K: Travere Therapeutics' FILSPARI sNDA Accepted by FDA for Traditional Approval in FSGS

Travere Therapeutics announces the FDA's acceptance of its supplemental New Drug Application (sNDA) for FILSPARI in treating focal segmental glomerulosclerosis (FSGS), with a PDUFA target action date set for January 13, 2026.

Summary

• Travere Therapeutics announced that the FDA has accepted its sNDA for traditional approval of FILSPARI for the treatment of FSGS.
• The FDA has assigned a PDUFA target action date of January 13, 2026, and plans to hold an advisory committee meeting to discuss the application.
• The sNDA is supported by results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study.
• If approved, FILSPARI could become the first and only FDA-approved medicine indicated for FSGS, a rare kidney condition affecting over 40,000 patients in the U.S.
• The Phase 3 DUPLEX Study achieved its pre-specified interim FSGS partial remission of proteinuria (FPRE) endpoint with statistical significance at 36 weeks but did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment.
• Two-year results from the DUPLEX study showed clinically meaningful benefit at 108 weeks with significant proteinuria reduction, higher rates of partial and complete remission, and a lower rate of end-stage kidney disease compared to the active control.
• The Phase 2 DUET Study demonstrated a greater than two-fold reduction in proteinuria compared to irbesartan.
• Sparsentan was well-tolerated with a safety profile comparable to the active control, irbesartan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the FDA's acceptance of the sNDA and the potential for FILSPARI to become the first approved treatment for FSGS. However, risks associated with regulatory approval and commercialization temper the overall sentiment.

Positives

• FDA acceptance of the sNDA for FILSPARI indicates progress towards potential approval.
• The PDUFA target action date provides a timeline for a decision.
• The potential for FILSPARI to be the first approved treatment for FSGS represents a significant market opportunity.
• Clinical trial results from the DUPLEX and DUET studies support the efficacy and safety of FILSPARI.
• The DUPLEX study showed clinically meaningful benefit at 108 weeks with significant proteinuria reduction, higher rates of partial and complete remission, and a lower rate of end-stage kidney disease compared to the active control.
• The Phase 3 DUPLEX Study achieved its pre-specified interim FSGS partial remission of proteinuria (FPRE) endpoint with statistical significance at 36 weeks.
• The Phase 2 DUET Study demonstrated a greater than two-fold reduction in proteinuria compared to irbesartan.

Negatives

• The Phase 3 DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment.

Risks

• There is no guarantee that the FDA will approve FILSPARI for FSGS on the anticipated timeline, or at all.
• The company faces risks related to the commercial launch of FILSPARI in IgAN.
• The company faces risks associated with the regulatory review and approval process.
• The company faces risks associated with enrollment of clinical trials for rare diseases.
• Ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons.
• Market acceptance of commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies is a risk.
• Challenges of manufacturing scale-up pose a risk.
• The company faces risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI.
• The company faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions.
• The company faces risks relating to the company's dependence on contractors for clinical drug supply and commercial manufacturing.
• Uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties pose a risk.
• The company faces risks associated with regulatory interactions.
• The company faces risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the company's products, and technological changes that may limit demand for the company's products.
• The company faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations.

Future Outlook

The company anticipates a potential FDA decision on FILSPARI for FSGS by January 13, 2026, and is preparing for a possible advisory committee meeting.

Industry Context

The announcement is significant as there is currently no approved pharmacologic indicated for the treatment of FSGS, making FILSPARI a potential first-in-class treatment option.

Comparison to Industry Standards

• Currently, there are no directly comparable FDA-approved therapies for FSGS, making FILSPARI's potential approval a novel advancement.
• Other companies developing treatments for glomerular diseases include Retrophin (now Travere Therapeutics), Calliditas Therapeutics (developing treatments for IgA nephropathy), and various companies pursuing therapies for other rare kidney disorders.
• The DUPLEX study, being the largest interventional study to date in FSGS, sets a high benchmark for future clinical trials in this rare disease.

Stakeholder Impact

• Positive impact on patients with FSGS if FILSPARI is approved, providing a new treatment option.
• Potential positive impact on shareholders due to increased revenue and market share if FILSPARI is approved.
• Potential positive impact on employees through job security and growth opportunities.

Next Steps

• The FDA will review the sNDA and potentially hold an advisory committee meeting.
• The company awaits the FDA's decision by the PDUFA target action date of January 13, 2026.
• The company will continue to prepare for the commercial launch of FILSPARI, pending FDA approval.

Key Dates

Keywords

FILSPARI, sparsentan, FSGS, FDA, sNDA, Travere Therapeutics, DUPLEX Study, DUET Study, PDUFA, Kidney Disease